NKG2D-CAR NK cell therapy (Hangzhou Converd )

NKG2D-CAR NK细胞疗法（杭州康万达）

Report date: 2022/09/28 10:43:15

Base Information

Drug NameNKG2D-CAR NK cell therapy (Hangzhou Converd )

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNKG2D ligands antagonists

TargetsNKG2D ligands

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesHangzhou Converd Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Third Affiliated Hospital Of Guangzhou Medical University

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A